Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts

Abstract

The Cholesterol-Lowering Atherosclerosis Study (CLAS) was a randomized, placebo-controlled, angiographic trial testing combined colestipol hydrochloride and niacin therapy in 162 nonsmoking men aged 40 to 59 years with previous coronary bypass surgery. During two years of treatment there was a 26% reduction in total plasma cholesterol, a 43% reduction in low-density lipoprotein cholesterol, plus a simultaneous 37% elevation of high-density lipoprotein cholesterol. This resulted in a significant reduction in the average number of lesions per subject that progressed (<i>P</i>&lt;.03) and the percentage of subjects with new atheroma formation (<i>P</i>&lt;.03) in native coronary arteries. Also, the percentage of subjects with new lesions (<i>P</i>&lt;.04) or any adverse change in bypass grafts (<i>P</i>&lt;.03) was significantly reduced. Deterioration in overall coronary status was significantly less in drug-treated subjects than placebo-treated subjects (<i>P</i>&lt;.001). Atherosclerosis regression, as indicated by perceptible improvement in overall coronary status, occurred in 16.2% of colestipol-niacin treated vs 2.4% placebo treated (<i>P</i>=.002). (<i>JAMA</i>1987;257:3233-3240)